Zydus Lifesciences Restricted acquired last approval from the US Meals and Drug Administration (USFDA) to fabricate Ketoconazole Shampoo, 2 per cent, in accordance with the announcement issued by the corporate at present.
The shares of Zydus Lifesciences Restricted had been buying and selling at 906.80 up by ₹6 or 0.67 per cent on the NSE at present at 10.25 am.
The antifungal medicine, used to deal with dandruff and fungal pores and skin infections, can be produced on the firm’s topical manufacturing facility in Changodar, Ahmedabad. The product is the generic equal of Nizoral Shampoo, 2 per cent.
The approval provides to Zydus’s rising pharmaceutical portfolio within the US market, the place Ketoconazole shampoo generated annual gross sales of $68.89 million in accordance with IQVIA knowledge from January 2025.
With this newest approval, Zydus now holds 418 approvals from the USFDA. The corporate has filed 483 Abbreviated New Drug Purposes (ANDAs), because it started the submitting course of in fiscal yr 2003-04, as reported within the firm’s knowledge by means of December 31, 2024.
